Passive accumulation relies on tumour vasculature architecture; active targeting adds a molecular address. The two are complementary, and the second only works when the first is under control.
How we work on it
Every programme in this area follows the same staged path: target definition, carrier or formulation engineering, validation in physiologically relevant models, then transfer to continuous-flow GMP production. Read the full technology overview or talk to the team.